rabbit polyclonal anti phosphorylated tak1  (Cusabio)

Journal: International Journal of Molecular Sciences

Article Title: Inflammatory Cytokine-Induced Muscle Atrophy and Weakness Can Be Ameliorated by an Inhibition of TGF-β-Activated Kinase-1

doi: 10.3390/ijms25115715

Figure Lengend Snippet: TNF-α and IL-1β enhanced TAK1 signaling, and LLZ abrogated TAK1 signaling in C2C12 cells. Western blot analysis of intracellular IκBα, phosphorylated TAK1, p38, and ERK in C2C12 cells treated with ( A ) TNF-α or ( B ) IL-1β in the presence or absence of LLZ.

Article Snippet: The following reagents were purchased from the indicated manufactures: mouse monoclonal antibodies against TNF-α and IL-1β, rabbit polyclonal antibodies against TAK1, IκBα, rabbit monoclonal antibodies against phosphorylated p38 MAPK, p38 MAPK, phosphorylate ERK, ERK, β-actin, horseradish peroxidase (HRP) anti-rabbit IgG, and anti-mouse IgG from Cell Signaling Technology (Beverly, MA, USA); antibodies against myosin heavy chain and goat IgG-FITC from Santa Cruz (Dallas, TX, USA); rabbit polyclonal anti-phosphorylated TAK1 from Cusabio (Houston, TX, USA); rabbit polyclonal antibodies against albumin from Invitrogen (Waltham, MA, USA); TAK1 inhibitor, LL-Z1640-2 (LLZ), from BioAustralis (Smithfield, NSW, Australia); recombinant human IL-1β from Wako (Osaka, Japan); recombinant human TNF-α from R&D Systems (Minneapolis, MN, USA); mannan from Sigma-Aldrich (St. Louis, MO, USA).

Techniques: Western Blot